Acadia (NASDAQ: ACAD) projects 2025 net sales will exceed $1 billion

Rhea-AI Filing Summary

Acadia Pharmaceuticals Inc. reported at the J.P. Morgan Healthcare Conference that it anticipates 2025 net sales will exceed $1 billion, in line with its prior guidance. The company shared this outlook in a corporate slide presentation and has made the slides available in the investors section of its website at ir.acadia.com. The update was furnished in a current report under results of operations and financial condition and accompanying Regulation FD disclosure.

Insights

Biopharma equity analyst

Acadia reaffirmed that 2025 net sales are expected to exceed $1 billion.

Acadia Pharmaceuticals used its J.P. Morgan Healthcare Conference presentation to state that it anticipates $1 billion or more in 2025 net sales, explicitly noting this is consistent with prior guidance. This signals management is maintaining its outlook rather than revising it.

The disclosure is furnished under results of operations and a Regulation FD item, which helps ensure all investors receive the same information at the same time. Because the company characterizes the >$1 billion expectation as aligned with earlier guidance, the statement functions more as a confirmation of prior expectations than a change in direction.

The slide deck referenced as Exhibit 99.1 and posted at the investor website may provide additional context around how management expects to reach net sales exceeding $1 billion in 2025, but those details are not described here. Future periodic reports can show whether actual reported net sales track this anticipated level.

False000107049400010704942026-01-132026-01-13

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 13, 2026

Acadia Pharmaceuticals Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			000-50768	06-1376651
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
12830 El Camino Real, Suite 400
San Diego, California				92130
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 558-2871

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		ACAD		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On January 13, 2026, Acadia Pharmaceuticals, Inc. (the “Company”) presented at the J.P. Morgan Healthcare Conference announcing, among other things, that it anticipates 2025 net sales will exceed $1 billion, consistent with prior guidance. In connection with such presentation, the Company posted a corporate slide presentation in the “Investors” portion of its website at ir.acadia.com.

Item 7.01 Regulation FD Disclosure.

The disclosure set forth in Item 2.02 above is incorporated by reference into this Item 7.01.

The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Acadia Pharmaceuticals Inc.
Date:	January 13, 2026		By:	/s/ Jennifer J. Rhodes
				Jennifer J. Rhodes
				Executive Vice President, Chief Legal Officer & Secretary

FAQ

What 2025 sales outlook did Acadia Pharmaceuticals (ACAD) share?

Acadia Pharmaceuticals stated that it anticipates 2025 net sales will exceed $1 billion, and noted this expectation is consistent with its prior guidance.

Where did Acadia (ACAD) provide the 2025 net sales guidance update?

The company presented this outlook at the J.P. Morgan Healthcare Conference and furnished the information in a current report under results of operations and financial condition.

Is Acadia’s 2025 net sales guidance new or a change from prior expectations?

Acadia described its expectation that 2025 net sales will exceed $1 billion as consistent with prior guidance, indicating it is a reaffirmation rather than a revision.

Where can investors access Acadia Pharmaceuticals’ latest slide presentation?

The company posted a corporate slide presentation related to the J.P. Morgan Healthcare Conference in the “Investors” section of its website at ir.acadia.com.

How was the 2025 guidance information treated for SEC liability purposes?

The information, including Exhibit 99.1, was furnished and not filed, meaning it is not deemed filed under Section 18 of the Exchange Act or automatically incorporated into other filings unless specifically referenced.

Which SEC items did Acadia use to disclose its 2025 net sales expectations?

The company used Item 2.02 (Results of Operations and Financial Condition), and that disclosure was also incorporated by reference into Item 7.01 (Regulation FD Disclosure).